H Hong1, D W Dowdy2, K E Dooley3, H W Francis4, C Budhathoki5, H-R Han6, J E Farley1. 1. Johns Hopkins University School of Nursing, Baltimore, MD, The REACH Initiative, Johns Hopkins University School of Nursing, Baltimore, MD. 2. Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Divisions of Clinical Pharmacology and Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD. 4. Division of Head and Neck Surgery and Communication Sciences, Duke University School of Medicine, Durham, NC. 5. Johns Hopkins University School of Nursing, Baltimore, MD. 6. Johns Hopkins University School of Nursing, Baltimore, MD, Center for Cardiovascular and Chronic Care, Johns Hopkins University, Baltimore, MD, USA.
Abstract
SETTING: The ototoxic effects of aminoglycosides (AGs) lead to permanent hearing loss, which is one of the devastating consequences of multidrug-resistant tuberculosis (MDR-TB) treatment. As AG ototoxicity is dose-dependent, the impact of a surrogate measure of AG exposure on AG-induced hearing loss warrants close attention for settings with limited therapeutic drug monitoring. OBJECTIVE: To explore the prognostic impact of cumulative AG dose on AG ototoxicity in patients following initiation of AG-containing treatment for MDR-TB. DESIGN: This prospective cohort study was nested within an ongoing cluster-randomized trial of nurse case management intervention across 10 MDR-TB hospitals in South Africa. RESULTS: The adjusted hazard of AG regimen modification due to ototoxicity in the high-dose group (≥75 mg/kg/week) was 1.33 times higher than in the low-dose group (<75 mg/kg/week, 95%CI 1.09-1.64). The adjusted hazard of developing audiometric hearing loss was 1.34 times higher than in the low-dose group (95%CI 1.01-1.77). Pre-existing hearing loss (adjusted hazard ratio [aHR] 1.71, 95%CI 1.29-2.26) and age (aHR 1.16 per 10 years of age, 95%CI 1.01-1.33) were also associated with an increased risk of hearing loss. CONCLUSION: MDR-TB patients with high AG dose, advanced age and pre-existing hearing loss have a significantly higher risk of AG-induced hearing loss. Those at high risk may be candidates for more frequent monitoring or AG-sparing regimens.
RCT Entities:
SETTING: The ototoxic effects of aminoglycosides (AGs) lead to permanent hearing loss, which is one of the devastating consequences of multidrug-resistant tuberculosis (MDR-TB) treatment. As AG ototoxicity is dose-dependent, the impact of a surrogate measure of AG exposure on AG-induced hearing loss warrants close attention for settings with limited therapeutic drug monitoring. OBJECTIVE: To explore the prognostic impact of cumulative AG dose on AG ototoxicity in patients following initiation of AG-containing treatment for MDR-TB. DESIGN: This prospective cohort study was nested within an ongoing cluster-randomized trial of nurse case management intervention across 10 MDR-TB hospitals in South Africa. RESULTS: The adjusted hazard of AG regimen modification due to ototoxicity in the high-dose group (≥75 mg/kg/week) was 1.33 times higher than in the low-dose group (<75 mg/kg/week, 95%CI 1.09-1.64). The adjusted hazard of developing audiometric hearing loss was 1.34 times higher than in the low-dose group (95%CI 1.01-1.77). Pre-existing hearing loss (adjusted hazard ratio [aHR] 1.71, 95%CI 1.29-2.26) and age (aHR 1.16 per 10 years of age, 95%CI 1.01-1.33) were also associated with an increased risk of hearing loss. CONCLUSION: MDR-TBpatients with high AG dose, advanced age and pre-existing hearing loss have a significantly higher risk of AG-induced hearing loss. Those at high risk may be candidates for more frequent monitoring or AG-sparing regimens.
Authors: T Törün; G Güngör; I Ozmen; Y Bölükbaşi; E Maden; B Biçakçi; G Ataç; T Sevim; K Tahaoğlu Journal: Int J Tuberc Lung Dis Date: 2005-12 Impact factor: 2.373
Authors: James A Seddon; Peter Godfrey-Faussett; Kayleen Jacobs; Adam Ebrahim; Anneke C Hesseling; H Simon Schaaf Journal: Eur Respir J Date: 2012-06-14 Impact factor: 16.671
Authors: Vaira Leimane; Vija Riekstina; Timothy H Holtz; Evija Zarovska; Vija Skripconoka; Lorna E Thorpe; Kayla F Laserson; Charles D Wells Journal: Lancet Date: 2005 Jan 22-28 Impact factor: 79.321
Authors: Karen Shean; Elizabeth Streicher; Elize Pieterson; Greg Symons; Richard van Zyl Smit; Grant Theron; Rannakoe Lehloenya; Xavier Padanilam; Paul Wilcox; Tommie C Victor; Paul van Helden; Martin P Grobusch; Martin Groubusch; Robin Warren; Motasim Badri; Keertan Dheda Journal: PLoS One Date: 2013-05-07 Impact factor: 3.240
Authors: Holly A Taylor; David W Dowdy; Alexandra R Searle; Andrea L Stennett; Vadim Dukhanin; Alice A Zwerling; Maria W Merritt Journal: SSM Qual Res Health Date: 2022-01-28